According to research presented during the 21st annual scientific sessions of the American Society of Echocardiography (ASE) in San Diego this week, cardiac troponin plasma concentrations and longitudinal strain can predict the development of cardiotoxicity in patients treated with anthracyclines and trastuzumab chemotherapies.

MINNEAPOLIS--Vital Images debuted Vitrea Enterprise Suite 1.3 with new clinical capabilities at the Society of Imaging Informatics in Medicine (SIIM) annual conference last week.

Medtronic has launched its iPro2 fourth-generation continuous glucose monitoring system to better manage diabetes and glucose levels in patients.

Patients with suspected obstructive sleep apnea (OSA) may no longer have to spend an expensive and uncomfortable night at a sleep center to monitor their sleep-disordered breathing. Researchers at the Philadelphia VA Medical Center have shown that patients fare just as well using portable home monitors to detect OSA, according to a study presented at the recent American Thoracic Society (ATS) annual meeting in New Orleans.

Veterans with hypertension and diabetes who visited group medical clinics saw substantial improvements in blood pressure rates, but not glycemic control, according to a study published June 1 in the Annals of Internal Medicine.

The challenge with any imaging technology is to improve and lead to better patient care. Regarding echocardiography, the challenge is not only to become more accurate, but also to become more reproducible.

Office-based nuclear cardiology practices are currently re-prioritizing, primarily due to reimbursement cuts called for in the 2010 Medicare Physician Fee Schedule. To keep their practices afloat, nuclear cardiologists are paying attention to several factors, including appropriate patient selection, improved lab management and cautious investment in technology.

Medtronics Resolute zotarolimus-eluting stent was found to be as safe and effective as Abbott Vasculars Xience V everolimus-eluting stent in a predominantly off-label population, based on the results of the RESOLUTE all-comers trial, presented Tuesday by Patrick W. Serruys MD, PhD, at EuroPCR in Paris. Slides